Court Approves Vermillion's Plan of Reorganization; Company Raises $43M

The confirmation of Vermillion's reorganization plan allows it to move ahead on its plans to bring its OVA1 test to market and to restart the development of other diagnostics.

Full-text access for premium subscribers only. Existing premium subscribers login here.
New to GenomeWeb? Register quickly here.